The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...

The Ducks wrapped up the regular season with an 80-73 victory against Washington on Sunday at Alaska Airlines Arena in Seattle to extend their winning streak to seven games. Senior center Nate ...

"Go-backs are a problem on a normal day. So imagine that hundreds of shoppers did it as part of an organized action, for days on end," Robin Washington writes. (M. Spencer Green/The Associated Press) ...

Most recently, with support from Gilead Sciences, ETR implemented the Intentional Advocates project which worked intensively with six organizations on capacity-building plans and aided their strategic ...

This leads investors to also remain optimistic about rising dividends in the future. Gilead Sciences has a better P/E ratio of 305.37 than the aggregate P/E ratio of 65.67 of the Biotechnology ...

Salesforce announced that her successor will be the company's lead independent director Robin Washington, who will hold the title of chief operating and financial officer. Washington officially ...

In high finance, the key ratio used to measure how well a company converts reported profits into free cash flow (FCF) is the accrual ratio (from cashflow). The accrual ratio subtracts the FCF from ...

GILD opened at $116.04 on Wednesday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 52-week low of $62.07 and a 52-week ...

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need.